CD274 and cancer: Agents inhibiting the expression of PD‐L1 through blockade of the AKT/PI3K/MTOR or the RAS/MEK signaling pathways, and more generally drivers of PD‐L1 expression, could help sensitize cancer cells to immunotherapy at the onset in various tumor types (Alsuliman et al., 2015; Lastwika et al., 2016; Loi et al., 2016; Peng et al., 2016).